About Contact Us Careers

Infectious Disease Therapeutics Market Size and Forecast, by Mode of Treatment (Drugs, Vaccines); Target Organism; Infection Type; Distribution Channel - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 6407
  • Published Date: Sep 18, 2025
  • Report Format: PDF, PPT

Infectious Disease Therapeutics Market Outlook:

Infectious Disease Therapeutics Market size was valued at USD 134.06 billion in 2025 and is set to exceed USD 196.54 billion by 2035, registering over 3.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of infectious disease therapeutics is estimated at USD 138.77 billion.

Infectious Disease Therapeutics Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The infectious disease therapeutics market is witnessing significant growth lately, due to the rising prevalence of various infectious diseases, advancements in therapeutics treatments, and medical research. The consistent development in this field is driven by evolving trends such as gene editing technologies, immunotherapy combinations, nano-technology-based delivery systems, personalized consultations, and artificial intelligence-derived treatments. Genetically diverse populations across the globe are providing a significant opportunity for researchers, clinicians, and healthcare professionals to develop a precise healthcare framework with effective therapy interventions by leveraging genetic data and insights. Government agencies, pharmaceutical companies, and research institutions are striving together to explore advancement in the therapeutics field and address the global burden of infectious diseases.  

Key Infectious Disease Therapeutics Market Market Insights Summary:

  • Regional Highlights:

    • North America’s infectious disease therapeutics market is anticipated to capture 42.1% share by 2035, driven by aging population and strong research and development infrastructure.

  • Segment Insights:

    • The hospitals segment in the infectious disease therapeutics market is expected to capture a 55.10% share by 2035, attributed to the large patient base, use of advanced technologies, and streamlined treatments.
    • The antibacterial segment in the infectious disease therapeutics market is projected to see significant growth till 2035, driven by the rising prevalence of infectious diseases caused by bacteria.

  • Key Growth Trends:

    • Increasing prevalence of infectious disease
    • Government-led efforts

  • Major Challenges:

    • High treatment cost
    • Lack of skilled healthcare professionals

  • Key Players: Pfizer Inc, GlaxoSmithKline, plc, Merck & Co., F. Hoffmann-La Roche Ltd, AstraZeneca, Mylan N.V., Novartis AG, Sanofi.

Global Infectious Disease Therapeutics Market Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 134.06 billion
    • 2026 Market Size: USD 138.77 billion
    • Projected Market Size: USD 196.54 billion by 2035
    • Growth Forecasts: 3.9% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (42.1% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, China, Germany, United Kingdom, Japan
    • Emerging Countries: China, India, Japan, South Korea, Brazil

    • Last updated on : 18 September, 2025

Growth Drivers

  • Increasing prevalence of infectious disease: The rising prevalence of infectious diseases has become a significant growth driver for the infectious disease therapeutics market. Antibiotic-resistant bacteria, viral diseases such as HIV, hepatitis, and influenza, and fungal infections such as candidemia, and aspergillosis are found commonly in the aging population and immunocompromised population, making them prone to the infections. Moreover, climatic change, urbanization, and tourism also facilitate the spread of infectious diseases, demanding advanced and effective therapeutics. 
  • Government-led efforts: The initiatives proposed by governments play a vital role in combating the prevailing infectious diseases and give rise to the development of advanced therapeutic mechanisms resulting in improved public health. Governments across the globe have launched multi-purpose programs that facilitate support for research and development programs, supply chain networks for vaccines and treatments, and required funding and resources for innovations.

    For instance, the U.S., government’s National Action Plan for combating anti-biotic resistant bacteria prioritizes preventing the infection spread by reducing the need for antibiotics use. The government of India also implemented a National Health Mission initiative aimed at strengthening the country’s healthcare system by ensuring quality healthcare facilities in urban and rural areas.
  • Advancement in technology: The rising technological advancements in genomics, proteomics, and artificial intelligence have provided access to new avenues for effective diagnostics, treatments, and vaccinations. For instance, next-generation sequencing technologies have assisted in the prompt detection of pathogens, CRISPR has facilitated in development of vaccines, and nanotechnology has improved delivery and efficiency of the treatments. These breakthroughs have not only improved treatment efficacy but also accelerated the developments in therapeutics.

Challenges

  • High treatment cost: The high cost of treatment poses a multifaceted challenge in the growth of infectious disease therapeutics resulting in deteriorated health, a decline in economy, and failure of a proper healthcare system. Extensive research and developmental activities, the need for advanced technologies, and stringent quality control measures fuel up the total cost. Additionally, managing healthcare-associated infections (HAI) clubbed with patient management expenses increases the burden on the economy, especially for countries with low income can be challenging.
  • Lack of skilled healthcare professionals: One of the major drawbacks within the industry is dearth of proficient healthcare personnel. The process of manufacturing drugs and vaccines requires a high level of specialization which limits the pace of development due to the shortage of such professionals. Other concerns such as under-compensation to the physicians and para-medical personnel, the global health workforce crisis, and the lack of proper training and education can hamper infectious disease therapeutics market growth.

Infectious Disease Therapeutics Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

3.9%

Base Year Market Size (2025)

USD 134.06 billion

Forecast Year Market Size (2035)

USD 196.54 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Infectious Disease Therapeutics Market Segmentation:

Target organism Segment Analysis

The antibacterial segment holds a significant share in the infectious disease therapeutics market due to rising prevalence of infectious diseases caused by bacteria such as hepatitis A, influenza, tuberculosis, HIV, hepatitis C, pneumonia, and urinary tract infections. The antibacterial segment focuses on developing effective therapeutics to combat the growth of bacterial infections in the body. Key market players such as Merck & Co., Pfizer, and AstraZeneca are playing crucial roles in expanding their antibacterial portfolio and enhancing their capabilities to render effective therapeutic solutions in the industry.

 Distribution channelSegment Analysis

Hospitals segment is predicted to hold infectious disease therapeutics market share of more than 55.1% by 2035. Hospitals generally have a large inventory of antivirals, antibiotics, antibacterials, and antifungals making it a prominent reaching point for patients. Moreover, it has a strong focus on the availability of pivotal measures and requisite diagnostics tools to prevent infections. This segment is poised for continuous growth owing to the large patient base, the use of advanced technologies, prevailing telemedicine platforms, streamlined treatment schedules, and formulary management to optimize medication and electronic health records.

Our in-depth analysis of the global infectious disease therapeutics market includes the following segments:

Mode of Treatment
  • Vaccines
  • Drugs

Target Organism
  • Antifungal
  • Antiviral
  • Antibacterial
  • Anti-parasite

Infection Type
  • Viral
  • Parasitic
  • Fungal
  • Bacterial

Distribution Channel
  • Clinic
  • Hospitals
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Infectious Disease Therapeutics Market Regional Analysis:

North America Market Insights

North America infectious disease therapeutics market will account for a 42.1% revenue share by 2035. Factors such as the aging population, lucrative healthcare expenditure, and the presence of strong research and development infrastructure drive demand for technically advanced diagnostics tools, and treatments.

U.S., is the largest infectious disease therapeutics market in North America, owing to the existence of prominent players and robust pharmaceuticals, research institutions, and hospital infrastructure. The rising burden of infectious diseases has resulted in increasing demand for advanced therapeutics. Leading companies and local bodies are focused on developing novel therapeutics and tools to cater to this surging demand.

Canada is likely to be the fastest-growing country followed by the U.S. owing to its strong healthcare structure, high disposable incomes, favorable reimbursement policies, and adoption of high-tech diagnostics tools. For instance, the Vaccine and Infectious Disease Organization (VIDO) is expanding its expertise and infrastructure as Canada’s center for pandemic research by adding a new vaccine development center with containment level 4 capacity.

APAC Market Insights

The infectious disease therapeutics market in Asia Pacific is expected to witness steady growth during the forecast period attributable to a rise in infectious disease cases, financial aid by the government, and rapid adoption of advanced technologies.

In India, the market is driven by its large population, and continuous local government spending in advancing hospital facilities and infrastructure. With concern to provide healthcare benefits to every corner of the country making it affordable and accessible. In June 2023, INVEX Health announced to launch of India’s first oral fluid HIV self-test considerably more effective than traditional blood-based test.

Infectious Disease Therapeutics Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Infectious Disease Therapeutics Market Players:

    The strong presence and result-driven approach toward an effective healthcare system across the globe by pharmaceutical companies is shaping the environment for the infectious disease therapeutics market. Key players are focused on developing novel drugs and therapeutics to cater to rising burden of various infectious diseases. Some research institutes are also partnering with companies to assist in R&D projects while some companies are adopting several techniques such as mergers and acquisitions, joint ventures, product launches, and license agreements to enhance their product base and retain their market position. Here are some leading key players operating in the infectious disease therapeutics market:

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline plc.
    •  Merck & Co.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Sun Pharma Industries Ltd.
    • Cipla Ltd.

Recent Developments

  • In April 2024, AstraZeneca showcased its new clinical, real-world, and early science data across its Vaccines & Immune Therapies portfolio at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain.
  • In September 2023, Moderna announced the expansion of its mRNA medicine for rare diseases, cancer, and infectious diseases.
  • Report ID: 6407
  • Published Date: Sep 18, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of infectious disease therapeutics is estimated at USD 138.77 billion.

The global infectious disease therapeutics market size crossed USD 134.06 billion in 2025 and is likely to register a CAGR of around 3.9%, exceeding USD 196.54 billion revenue by 2035.

North America’s infectious disease therapeutics market is anticipated to capture 42.1% share by 2035, driven by aging population and strong research and development infrastructure.

Key players in the market include Pfizer Inc, GlaxoSmithKline, plc, Merck & Co., F. Hoffmann-La Roche Ltd, AstraZeneca, Mylan N.V., Novartis AG, Sanofi.

Infectious Disease Therapeutics Market Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos